393 related articles for article (PubMed ID: 31028540)
21. Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.
Haas B; Ciftcioglu J; Jermar S; Weickhardt S; Eckstein N; Kaina B
J Cancer Res Clin Oncol; 2021 Mar; 147(3):779-792. PubMed ID: 33315125
[TBL] [Abstract][Full Text] [Related]
22. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
23. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
[TBL] [Abstract][Full Text] [Related]
24. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
25. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
26. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
27. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
28. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH
Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539
[TBL] [Abstract][Full Text] [Related]
30. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.
Halatsch ME; Kast RE; Dwucet A; Hlavac M; Heiland T; Westhoff MA; Debatin KM; Wirtz CR; Siegelin MD; Karpel-Massler G
Br J Pharmacol; 2019 Sep; 176(18):3681-3694. PubMed ID: 31222722
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
Buccarelli M; Marconi M; Pacioni S; De Pascalis I; D'Alessandris QG; Martini M; Ascione B; Malorni W; Larocca LM; Pallini R; Ricci-Vitiani L; Matarrese P
Cell Death Dis; 2018 Aug; 9(8):841. PubMed ID: 30082680
[TBL] [Abstract][Full Text] [Related]
32. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
33. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
35. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma.
Wang Y; Huang N; Li H; Liu S; Chen X; Yu S; Wu N; Bian XW; Shen HY; Li C; Xiao L
Oncotarget; 2017 Jun; 8(23):37511-37524. PubMed ID: 28415586
[TBL] [Abstract][Full Text] [Related]
36. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
[TBL] [Abstract][Full Text] [Related]
37. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
38. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
39. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
[TBL] [Abstract][Full Text] [Related]
40. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
